You are here: Industry Insights > Regeneron

News List

PCSK9 price-cut matchup is on, as Regeneron and Sanofi slash Praluent list tag 60% fiercepharma
February 24, 2019
It’s not often that a tit-for-tat pricing battle goes public in biopharma—and that sort of fight is perhaps even more rare for prerebate list prices.
Regeneron and Sanofi cut US list price of Praluent pharmaceutical-technology
February 13, 2019
Regeneron and Sanofi have announced they have lowered the list price of high cholesterol drug Praluent (alirocumab) in the US by approximately 60%....
Regeneron's Eylea hits double-digit growth for 2018, and it's 'far from done fiercepharma
January 10, 2019
Investors had been worried that growth for Regeneron’s Eylea was slowing down, but the New York drugmaker kicked off the J.P. Morgan Healthcare Conference with an attempt to allay those fears.
Sanofi to pay Regeneron $462 million in revised immuno-oncology deal expressbpd
January 09, 2019
The two companies said the new arrangement would give Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline, while Regeneron retains all rights to its other immuno-oncology discovery and development programmes
Sanofi revises immuno-oncology deal with Regeneron pharmaceutical-technology
January 08, 2019
Sanofi and Regeneron Pharmaceuticals have revised a global immuno-oncology discovery and development agreement to develop new treatments for cancer......
Regeneron records 80% complete response rate in lymphoma trial fiercebiotech
January 03, 2019
Regeneron’s CD20xCD3 bispecific antibody has achieved an 80% complete response rate in a small trial of patients with relapsed or refractory follicular lymphoma....
FDA approves Regeneron, Sanofi's Dupixent for asthma treatment biospectrumasia
November 26, 2018
The FDA approves Regeneron Pharmaceuticals and development partner Sanofi's DUPIXENT (dupilumab) as add-on maintenance therapy in patients with
Sanofi and Regeneron’s Dupixent gets more positive feedback from US FDA expressbpd
November 08, 2018
Dupixent was launched in the US in April 2017 for the treatment of moderate-to-severe eczema
Priority review for Sanofi, Regeneron’s Dupixent pharmatimes
November 08, 2018
Sanofi and Regeneron’s biologic Dupixent has been granted a priority review in the US for use to treat certain adolescent patients with moderate-to-severe atopic dermatitis.
Two-year AMD study data reaffirm superiority of Novartis' brolucizumab at reducing retinal fluid, thickness versus Regeneron's Eylea firstwordpharma
October 29, 2018
Two-year AMD study data reaffirm superiority of Novartis' brolucizumab at reducing retinal fluid, thickness versus Regeneron's Eylea

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page